XXXX in Augmented Breasts: MRI Findings.

@entity1 @entity1137 @entity0 @entity5 @entity189 @entity513
OBJECTIVE: The objective of our study was to characterize the MRI features of @entity0 detected in augmented breasts. MATERIALS AND METHODS: A review of the MRI database identified 54 @entity1 with biopsy-proven @entity0 in augmented breasts. The images were reviewed for the type and location of the implant and for the characteristics of the @entity189 . The cases included 46 (85%) invasive @entity5 ( @entity513 , n = 35; @entity1137 , n = 7; and mixed features, n = 4) and eight (15%) @entity513 in situ. RESULTS: The median age of the @entity1 at diagnosis was 49 years (range, 28-72 years). Thirty-eight of the 54 @entity5 (70%) were palpable. The mean @entity5 size was 2.8 cm (range, 0.6-9.6 cm). Of the 54 @entity5 , 34 (63%) presented as masses and 20 (37%) as nonmass enhancement on MRI. There was no detectable difference between implant position and lesion morphology (p = 0.55) or @entity5 size (p = 1.00). Twenty of 54 (37%) @entity189 abutted the implant, 13 (24%) abutted the pectoralis major muscle, and two (4%) invaded the pectoralis major muscle. Of the @entity5 abutting the implant, 18 of 20 (90%) spread along the implant capsule for more than 0.5 cm. This pattern of @entity5 spread was more common in breasts with retroglandular implants (9/16, 56%) than in those with retropectoral implants (9/38, 24%) (p = 0.03). MRI detected the index @entity189 in 16 of 54 (30%) cases, showed a greater extent of disease than was visible on mammography or ultrasound in 21 of 52 (40%) cases, and detected an unsuspected @entity189 in three of 54 (6%) cases. CONCLUSION: In augmented breasts, @entity0 often contacts either the implant or the pectoralis major muscle. @entity5 spread along the implant contour is more often seen with retroglandular implants than with retropectoral implants. MRI should be considered to assess disease extent in @entity1 with augmented breasts before surgery.
